Boston Scientific shares fall 55% amid challenges but underlying business shows growth potential

Boston Scientific's stock dropped 55% over the past year, mainly due to weak performance in its electrophysiology and WATCHMAN segments, which make up 26% of expected 2025 sales. Despite this, 74% of the company's business grew by a strong 7% in Q2 2026, indicating solid underlying strength. Management has cut 2026 guidance three times, lowering organic growth to 5-6% and EPS guidance to $3.28-$3.32, which has increased investor pessimism. However, expectations are for the company to return to 5-7% growth and improved EPS guidance in 2027, suggesting a potential stock rebound.

Boston Scientific trades at USD 44.18 on Pluang as of Sep 29, 2026 16:21 WIB, close to its 52-week low of USD 42.63. Despite the stock's 55% drop over the past year noted in the article, Pluang data shows a slight 1-day gain of 0.16%. Investor interest remains strong with 94% of Pluang orders buying the stock, reflecting ongoing optimism amid the company's mixed outlook.